Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIT1 | Q13231 | 6/20 | 0.44 |
| ▸ | CHIA | Q9BZP6 | 6/20 | 0.44 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.44 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7464765 | 0.89 | GRIN2B (0.39) | CHIT1CHIACHI3L1CHI3L2GRIN2B | |
| SCHEMBL1967611 | 0.80 | CHIA (0.54) | CHIT1CHIACHI3L1CHI3L2GRIN2B | |
| SCHEMBL1968987 | 0.80 | CHIA (0.54) | CHIT1CHIACHI3L1CHI3L2GRIN2B | |
| SCHEMBL1242233 | 0.79 | TAAR1 (0.60) | CHIT1CHIACHI3L1CHI3L2GRIN2B | |
| SCHEMBL1969047 | 0.79 | TAAR1 (0.60) | CHIT1CHIACHI3L1CHI3L2GRIN2B | |
| SCHEMBL27817743 | 0.79 | HTR2A (0.49) | CHIT1CHIACHI3L1CHI3L2GRIN2B | |
| SCHEMBL27817745 | 0.79 | CHIT1 (0.63) | CHIT1CHIACHI3L1CHI3L2GRIN2B | |
| SCHEMBL1967143 | 0.78 | GRIN2B (0.63) | CHIAGRIN2BHTR2ASLC18A3 | |
| SCHEMBL7473318 | 0.78 | MCHR1 (0.47) | HRH3 | |
| SCHEMBL1966648 | 0.76 | TAAR1 (0.47) | CHIT1CHIACHI3L1CHI3L2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | CHIT1 4004/4885CHIA 1645/4885CHI3L1 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.